一品红(300723.SZ)：收到控股股东支持公司发展承诺

Core Viewpoint - The company received a commitment letter from its controlling shareholder, Guangdong Guangrun Group, expressing strong confidence in the acquisition of Arthrosi and the market potential of its gout innovation drug, AR882, in Greater China [1] Group 1 - Guangrun Group anticipates that the company will continue to innovate and develop more drugs to benefit patients, thereby supporting the company's stable and healthy growth [1] - The commitment includes a promise that after the completion of the acquisition, Guangrun Group will transfer its 9.07% stake in Arthrosi, valued at $383 million post-E round investment, to the company without any conditions [1]